keyword
MENU ▼
Read by QxMD icon Read
search

predictive biomarker bevacizumab

keyword
https://www.readbyqxmd.com/read/29438092/randomized-phase-ii-trial-of-parsatuzumab-anti-egfl7-or-placebo-in-combination-with-carboplatin-paclitaxel-and-bevacizumab-for-first-line-nonsquamous-non-small-cell-lung-cancer
#1
Joachim von Pawel, David R Spigel, Thomas Ervin, György Losonczy, Fabrice Barlesi, Erzsébet Juhász, Maria Anderson, Bruce McCall, Eric Wakshull, Priti Hegde, Weilan Ye, Daniel Chen, Ilsung Chang, Ina Rhee, Martin Reck
LESSONS LEARNED: The lack of efficacy associated with anti-EGFL7 combined with standard bevacizumab and chemotherapy in this phase II trial in non-small cell lung carcinoma is consistent with the lack of benefit observed in colorectal carcinoma, highlighting the challenge of enhancing the efficacy of VEGF inhibition in unselected populations.Future efforts with agents like anti-EGFL7 should be guided by advances in pharmacodynamic and predictive biomarker development for antiangiogenic agents...
February 7, 2018: Oncologist
https://www.readbyqxmd.com/read/29424297/use-of-immunotherapy-to-treat-metastatic-breast-cancer
#2
Andrea Nicolini, Vivian Barak, Piermario Biava, Paola Ferrari, Giuseppe Rossi, Angelo Carpi
This article reviews the principal attempts of immune-modulation or immune therapy in metastatic breast cancer. It considers their rationale and reports on results from the relevant key clinical trials. Immune-modulatory or immune-stimulating cytokines used alone or combined with conventional therapies is among the principal approaches of immune manipulation in breast cancer. As this issue was recently reviewed by us, the aim of the current article is to discuss our updated and unpublished data on this topic...
February 9, 2018: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/29410027/pro-metastatic-activity-of-agr2-interrupts-angiogenesis-target-bevacizumab-efficiency-via-direct-interaction-with-vegfa-and-activation-of-nf-%C3%AE%C2%BAb-pathway
#3
Mengqi Jia, Yanxia Guo, Deyu Zhu, Nianzhao Zhang, Lin Li, Jin Jiang, Yiwen Dong, Qingqing Xu, Xiulei Zhang, Jin Jiang, Meijuan Wang, Haina Yu, Fang Wang, Keli Tian, Jinsan Zhang, Charles Y F Young, Hongxiang Lou, Huiqing Yuan
Anterior gradient 2 (AGR2), an endoplasmic reticulum (ER)-resident protein-disulfide isomerase (PDI), is associated with cancer development and malignant progression. Here, we show that high level of AGR2 promotes the aggressive phenotype of prostate cancer (PCa) mouse models developed by either patient-derived xenografts or surgical intra-prostate implantation of PCa cells, associated with enrichment of the blood vessel network in tumor tissues. Angiogenesis markers VEGFR2 and CD34, accompanied with the invasive marker Vimentin, were predominantly stained in metastatic liver tissues...
January 30, 2018: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/29393706/biomarkers-in-recurrent-grade-iii-glioma-patients-treated-with-bevacizumab-and-irinotecan
#4
Anders Toft, Thomas Urup, Ib Jarle Christensen, Signe Regner Michaelsen, Babloo Lukram, Kirsten Grunnet, Michael Kosteljanetz, Vibeke Andrée Larsen, Ulrik Lassen, Helle Broholm, Hans Skovgaard Poulsen
Predictive biomarkers and prognostic models are required to identify recurrent grade III glioma patients who benefit from existing treatment. In this study of 62 recurrent grade III glioma patients, a range of clinical and paraclinical factors are tested for association with progression-free survival, overall survival, and response to bevacizumab and irinotecan therapy. Significant factors from univariate screening are included in multivariate analysis. Biomarkers previously advanced as predictive or prognostic in the first-line setting did not affect outcome in this patient cohort...
February 2, 2018: Cancer Investigation
https://www.readbyqxmd.com/read/29361687/circulating-plasma-levels-of-mir-20b-mir-29b-and-mir-155-as-predictors-of-bevacizumab-efficacy-in-patients-with-metastatic-colorectal-cancer
#5
Paola Ulivi, Matteo Canale, Alessandro Passardi, Giorgia Marisi, Martina Valgiusti, Giovanni Luca Frassineti, Daniele Calistri, Dino Amadori, Emanuela Scarpi
Targeting angiogenesis in the treatment of colorectal cancer (CRC) is a common strategy, for which potential predictive biomarkers have been studied. miRNAs are small non-coding RNAs involved in several processes including the angiogenic pathway. They are very stable in biological fluids, which turns them into potential circulating biomarkers. In this study, we considered a case series of patients with metastatic (m) CRC treated with a bevacizumab (B)-based treatment, enrolled in the prospective multicentric Italian Trial in Advanced Colorectal Cancer (ITACa)...
January 20, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29355613/histopathological-growth-patterns-as-a-candidate-biomarker-for-immunomodulatory-therapy
#6
REVIEW
Pieter-Jan van Dam, Sofie Daelemans, Elizabeth Ross, Yannick Waumans, Steven Van Laere, Emily Latacz, Roanne Van Steen, Christel De Pooter, Mark Kockx, Luc Dirix, Peter B Vermeulen
The encroachment of a growing tumor upon the cells and structures of surrounding normal tissue results in a series of histopathological growth patterns (HGPs). These morphological changes can be assessed in hematoxylin-and-eosin (H&E) stained tissue sections from primary and metastatic tumors and have been characterized in a range of tissue types including liver, lung, lymph node and skin. HGPs in different tissues share certain general characteristics like the extent of angiogenesis, but also appropriate tissue-specific mechanisms which ultimately determine differences in the biology of HGP subtypes...
January 17, 2018: Seminars in Cancer Biology
https://www.readbyqxmd.com/read/29350455/a-novel-prognostic-six-cpg-signature-in-glioblastomas
#7
An-An Yin, Nan Lu, Amandine Etcheverry, Marc Aubry, Jill Barnholtz-Sloan, Lu-Hua Zhang, Jean Mosser, Wei Zhang, Xiang Zhang, Yu-He Liu, Ya-Long He
AIMS: We aimed to identify a clinically useful biomarker using DNA methylation-based information to optimize individual treatment of patients with glioblastoma (GBM). METHODS: A six-CpG panel was identified by incorporating genome-wide DNA methylation data and clinical information of three distinct discovery sets and was combined using a risk-score model. Different validation sets of GBMs and lower-grade gliomas and different statistical methods were implemented for prognostic evaluation...
January 19, 2018: CNS Neuroscience & Therapeutics
https://www.readbyqxmd.com/read/29333924/dynamic-mr-imaging-for-functional-vascularization-depends-on-tissue-factor-signaling-in-glioblastoma
#8
Xiao Chen, Tian Xie, Jingqin Fang, Wei Xue, Houyi Kang, Haipeng Tong, Yu Guo, Bo Zhang, Sumei Wang, Yizeng Yang, Weiguo Zhang
Glomeruloid vascular proliferation (GVP) is a diagnostic hallmark and links to aggressive behavior, therapy resistance and poor prognosis in glioblastoma (GBM). It lacks clinical approaches to predict and monitor its formation and dynamic change. Yet the mechanism of GVPs also remains largely unknown. Using an in situ GBM xenograft mouse model, combined clinical MRI images of pre-surgery tumor and pathological investigation, we demonstrated that the inhibition of tissue factor (TF) decreased GVPs in Mouse GBM xenograft model...
January 15, 2018: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/29305787/molecular-profiling-of-short-term-and-long-term-surviving-patients-identifies-cd34-mrna-level-as-prognostic-for-glioblastoma-survival
#9
Signe Regner Michaelsen, Thomas Urup, Lars Rønn Olsen, Helle Broholm, Ulrik Lassen, Hans Skovgaard Poulsen
Despite extensive treatment, overall survival (OS) for glioblastoma (GBM) remains poor. A small proportion of patients present long survival over 3 years, but the underlying molecular background separating these long-term survivors (LTS) from short-term survivors (STS) are insufficiently understood. Accordingly, study aim was to identify independent prognostic biomarkers for survival. Study cohort consisted of 93 primary GBM patients treated with radiation-, chemo- and bevacizumab therapy, among which 14 STS (OS ≤ 12 months) and 6 LTS (OS ≥ 36 months) were identified, all confirmed being IDH wild-type...
January 5, 2018: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/29146617/cure-in-advanced-renal-cell-cancer-is-it-an-achievable-goal
#10
Dhanusha Sabanathan, John J Park, Manuel Marquez, Louise Francisco, Natalie Byrne, Howard Gurney
BACKGROUND: Immunotherapy has historically been of interest in the management of metastatic renal cell cancer (mRCC) because of its relative chemoresistance and the reproducible but low incidence of spontaneous remission in metastatic disease. Recently, targeted immunotherapies in the form of checkpoint inhibitors have shown durable responses in approximately 20%-30% of patients with solid tumors, with a much more acceptable side-effect profile. Anti-programmed death receptor 1 (PD-1)/programmed death receptor ligand 1 antibodies rely on the presence of host T cells in the tumor microenvironment to be stimulated in order to activate an antitumor response...
November 16, 2017: Oncologist
https://www.readbyqxmd.com/read/29134647/serial-profiling-of-circulating-tumor-dna-for-optimization-of-anti-vegf-chemotherapy-in-metastatic-colorectal-cancer-patients
#11
Masami Yamauchi, Yuji Urabe, Atsushi Ono, Daiki Miki, Hidenori Ochi, Kazuaki Chayama
Understanding the molecular changes in tumors in response to anti-VEGF chemotherapy is crucial for optimization of the treatment strategy for metastatic colorectal cancer. We prospectively investigated changes in the amount and constitution of circulating tumor DNA (ctDNA) in serial peripheral blood samples during chemotherapy. Sixty-one plasma samples taken at different time points (baseline, remission, and post-progression) and pre-treatment tumor samples were collected from 21 patients who received bevacizumab-containing first-line chemotherapy...
November 14, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29078212/-current-status-of-targeted-treatment-in-breast-cancer
#12
Katharina Seiffert, Barbara Schmalfeldt, Volkmar Müller
Within the last years, significant improvements have been achieved in breast cancer treatment, particularly with the development of targeted therapies. Major progress has been made in identifying the drivers malignant growth in oestrogen-receptor-positive breast cancer and the mechanisms of resistance to endocrine therapy. This progress has translated into several targeted therapies that enhance the efficacy of endocrine therapy; inhibitors of the cyclin-dependent kinases CDK4 and CDK6 like palbociclib and inhibitors of mTOR substantially improve progression-free survival...
November 2017: Deutsche Medizinische Wochenschrift
https://www.readbyqxmd.com/read/29064750/the-attenuation-distribution-across-the-long-axis-of-breast-cancer-liver-metastases-at-ct-a-quantitative-biomarker-for-predicting-overall-survival
#13
Richard G Abramson, Nikita Lakomkin, Allison Hainline, Hakmook Kang, M Shane Hutson, Carlos L Arteaga
OBJECTIVE: The objective of our study was to compare attenuation distribution across the long-axis (ADLA) measurements, Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, and Choi criteria for predicting overall survival (OS) in patients with metastatic breast cancer treated with bevacizumab. MATERIALS AND METHODS: We obtained HIPAA-compliant data from a prospective, multisite, phase 3 trial of bevacizumab for the treatment of metastatic breast cancer...
October 24, 2017: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/29059427/microvascular-density-as-a-predictive-biomarker-for-bevacizumab-survival-benefit-in-ovarian-cancer-back-to-first-principles
#14
Napoleone Ferrara
No abstract text is available yet for this article.
November 1, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29059426/tumor-microvessel-density-as-a-potential-predictive-marker-for-bevacizumab-benefit-gog-0218-biomarker-analyses
#15
RANDOMIZED CONTROLLED TRIAL
Carlos Bais, Barbara Mueller, Mark F Brady, Robert S Mannel, Robert A Burger, Wei Wei, Koen M Marien, Mark M Kockx, Amreen Husain, Michael J Birrer
Background: Combining bevacizumab with frontline chemotherapy statistically significantly improved progression-free survival (PFS) but not overall survival (OS) in the phase III GOG-0218 trial. Evaluation of candidate biomarkers was an exploratory objective. Methods: Patients with stage III (incompletely resected) or IV ovarian cancer were randomly assigned to receive six chemotherapy cycles with placebo or bevacizumab followed by single-agent placebo or bevacizumab...
November 1, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/28940389/assessment-of-early-response-biomarkers-in-relation-to-long-term-survival-in-patients-with-her2-negative-breast-cancer-receiving-neoadjuvant-chemotherapy-plus-bevacizumab-results-from-the-phase-2-promix-trial
#16
S Kimbung, I Markholm, J Bjöhle, T Lekberg, A von Wachenfeldt, E Azavedo, A Saracco, M Hellström, S Veerla, E Paquet, P O Bendahl, M Fernö, J Bergh, N Loman, T Hatschek, I Hedenfalk
Pathologic complete response (pCR) is a predictor for favorable outcome after neoadjuvant treatment in early breast cancer. Modulation of gene expression may also provide early readouts of biological activity and prognosis, offering the possibility for timely response-guided treatment adjustment. The role of early transcriptional changes in predicting response to neoadjuvant chemotherapy plus bevacizumab was investigated. One-hundred-and-fifty patients with large, operable and locally advanced HER2-negative breast cancer received epirubicin and docetaxel, with the addition of bevacizumab...
September 22, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28934120/angiogenesis-inhibitors-in-nsclc
#17
REVIEW
Anna Manzo, Agnese Montanino, Guido Carillio, Raffaele Costanzo, Claudia Sandomenico, Nicola Normanno, Maria Carmela Piccirillo, Gennaro Daniele, Francesco Perrone, Gaetano Rocco, Alessandro Morabito
Angiogenesis is a complex biological process that plays a relevant role in sustaining the microenvironment, growth, and metastatic potential of several tumors, including non-small cell lung cancer (NSCLC). Bevacizumab was the first angiogenesis inhibitor approved for the treatment of patients with advanced NSCLC in combination with chemotherapy; however, it was limited to patients with non-squamous histology and first-line setting. Approval was based on the results of two phase III trials (ECOG4599 and AVAIL) that demonstrated an improvement of about two months in progression-free survival (PFS) in both trials, and in the ECOG4599 trial, an improvement in overall survival (OS) also...
September 21, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28863773/down-regulation-of-mirna-148a-and-mirna-625-3p-in-colorectal-cancer-is-associated-with-tumor-budding
#18
Edita Baltruskeviciene, Diana Schveigert, Vaidotas Stankevicius, Ugnius Mickys, Tadas Zvirblis, Jaroslav Bublevic, Kestutis Suziedelis, Eduardas Aleknavicius
BACKGROUND: MiRNAs are often deregulated in colorectal cancer and might function as tumor suppressors or as oncogenes. They participate in controlling key signaling pathways involved in proliferation, invasion and apoptosis and may serve as prognostic and predictive markers. In this study we aimed to evaluate the role of miRNA-148a and miRNA-625-3p in metastatic colorectal cancer. METHODS: Fifty-four patients with a first-time diagnosed CRC receiving FOLFOX ± Bevacizumab were involved in the study...
September 1, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28837790/disorganization-of-the-retinal-inner-layers-as-a-predictor-of-visual-acuity-in-eyes-with-macular-edema-secondary-to-vein-occlusion
#19
MULTICENTER STUDY
Michael Mimouni, Or Segev, Dalia Dori, Noa Geffen, Victor Flores, Ori Segal
PURPOSE: To determine whether spectral-domain optical coherence tomography (SD-OCT) disorganization of the retinal inner layers (DRIL) is predictive of best-corrected visual acuity (BCVA) in retinal vein occlusion macular edema (RVO-ME). DESIGN: Retrospective cohort study. METHODS: Setting: Two tertiary centers. PATIENTS: Treatment-naïve RVO-ME receiving monthly intravitreal bevacizumab. OBSERVATION PROCEDURES: Spectral-domain optical coherence tomography (SD-OCT) images from baseline, 4-month, and 8-month visits...
October 2017: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/28819189/vascular-hysteresis-loops-and-vascular-architecture-mapping-in-patients-with-glioblastoma-treated-with-antiangiogenic-therapy
#20
Andreas Stadlbauer, Max Zimmermann, Stefan Oberndorfer, Arnd Doerfler, Michael Buchfelder, Gertraud Heinz, Karl Roessler
In this study, we investigated the variability of vascular hysteresis loop (VHL) shapes and the spatial heterogeneity of neovascularization and microvascular alterations using vascular architecture mapping (VAM) in patients with recurrent glioblastoma during bevacizumab mono-therapy. VAM data were acquired in 13 patients suffering from recurrent glioblastoma prior to and 3 months after bevacizumab treatment onset using a dual contrast agent injections approach as part of routine MRI. Two patients were additionally examined after the first cycle of bevacizumab to check for early treatment response...
August 17, 2017: Scientific Reports
keyword
keyword
93667
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"